NASDAQ:ONTX Onconova Therapeutics - ONTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.18 +0.04 (+3.51%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.11▼$1.2350-Day Range$0.63▼$1.4252-Week Range$0.62▼$2.04Volume164,253 shsAverage Volume289,206 shsMarket Capitalization$24.66 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Onconova Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside662.7% Upside$9.00 Price TargetShort InterestHealthy0.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.91) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector304th out of 1,027 stocksPharmaceutical Preparations Industry146th out of 500 stocks 3.5 Analyst's Opinion Consensus RatingOnconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Onconova Therapeutics has a forecasted upside of 662.7% from its current price of $1.18.Amount of Analyst CoverageOnconova Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.04% of the outstanding shares of Onconova Therapeutics have been sold short.Short Interest Ratio / Days to CoverOnconova Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconova Therapeutics has recently decreased by 12.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOnconova Therapeutics does not currently pay a dividend.Dividend GrowthOnconova Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONTX. Previous Next 2.9 News and Social Media Coverage News SentimentOnconova Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Onconova Therapeutics this week, compared to 0 articles on an average week.Search Interest5 people have searched for ONTX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows5 people have added Onconova Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Onconova Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.30% of the stock of Onconova Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Onconova Therapeutics are expected to grow in the coming year, from ($0.91) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconova Therapeutics is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconova Therapeutics is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconova Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Onconova Therapeutics (NASDAQ:ONTX) StockOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.Read More Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONTX Stock News HeadlinesFebruary 6, 2023 | finance.yahoo.comWe Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth CarefullyFebruary 1, 2023 | finance.yahoo.comOnconova Therapeutics to Present at the 2023 Guggenheim Oncology ConferenceFebruary 6, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 30, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comJanuary 26, 2023 | finance.yahoo.comOnconova Therapeutics Announces Participation in the Channelchek Takeaway SeriesJanuary 18, 2023 | reuters.comONTX.O - | Stock Price & Latest News | ReutersDecember 19, 2022 | finance.yahoo.comOnconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of DirectorsDecember 7, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor ConferenceFebruary 6, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…November 28, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth ConferenceNovember 17, 2022 | finance.yahoo.comOnconova Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsNovember 15, 2022 | seekingalpha.comOnconova Therapeutics, Inc. (ONTX) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comOnconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business UpdateNovember 15, 2022 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue EstimatesNovember 8, 2022 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022September 22, 2022 | au.finance.yahoo.comOnconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare ConferenceSeptember 22, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare ConferenceSeptember 20, 2022 | seekingalpha.comONTX Onconova Therapeutics, Inc.September 12, 2022 | seekingalpha.comOnconova rigosertib/Opdivo combo shows promise in advanced lung cancer in trialSeptember 12, 2022 | finance.yahoo.comOnconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022September 1, 2022 | finance.yahoo.comOnconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 11, 2022 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2022 | finance.yahoo.comOnconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 4, 2022 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022June 13, 2022 | seekingalpha.comOnconova Therapeutics appoints company's CFO Mark Guerin as the new COOJune 13, 2022 | finance.yahoo.comOnconova Therapeutics Announces Key Management PromotionsMay 26, 2022 | finance.yahoo.comOnconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical ModelsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONTX Company Calendar Last Earnings11/14/2022Today2/06/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees14Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+493.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,160,000.00 Net Margins-7,658.41% Pretax Margin-7,658.41% Return on Equity-43.20% Return on Assets-34.83% Debt Debt-to-Equity RatioN/A Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$230,000.00 Price / Sales107.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.53Miscellaneous Outstanding Shares20,900,000Free Float20,645,000Market Cap$24.66 million OptionableNot Optionable Beta1.81 Key ExecutivesSteven M. FruchtmanPresident, Chief Executive Officer & DirectorMark P. GuerinChief Operating & Financial OfficerMatthew ParrisVice President-Clinical OperationsMark Stephen GelderChief Medical OfficerAdar Makovski SilversteinSenior Director & Head-Corporate DevelopmentKey CompetitorsNightHawk BiosciencesNYSE:NHWKAeglea BioTherapeuticsNASDAQ:AGLELumos PharmaNASDAQ:LUMOPurple BiotechNASDAQ:PPBTAthenexNASDAQ:ATNXView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 100 shares on 2/2/2023Ownership: 0.000%Vanguard Group Inc.Bought 110,965 shares on 11/15/2022Ownership: 2.981%Two Sigma Advisers LPSold 52,773 shares on 11/15/2022Ownership: 0.604%Renaissance Technologies LLCSold 128,229 shares on 11/14/2022Ownership: 0.981%View All Institutional Transactions ONTX Stock - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. What is Onconova Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 1-year target prices for Onconova Therapeutics' stock. Their ONTX share price forecasts range from $7.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 650.0% from the stock's current price. View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts. How have ONTX shares performed in 2023? Onconova Therapeutics' stock was trading at $0.6457 at the start of the year. Since then, ONTX stock has increased by 85.8% and is now trading at $1.20. View the best growth stocks for 2023 here. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its quarterly earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 7,658.41% and a negative trailing twelve-month return on equity of 43.20%. When did Onconova Therapeutics' stock split? Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman. View institutional ownership trends. How do I buy shares of Onconova Therapeutics? Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $1.20. How much money does Onconova Therapeutics make? Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $25.08 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-16,160,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681. This page (NASDAQ:ONTX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.